Counterpoint: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer. Neoadjuvant Therapy Should Not Be Used as Part of Standard Clinical Practice
Oncology (Williston Park)
.
2018 Jan 15;32(1):39, 42-4.
Authors
Pablo Sala Elarre
,
Kenneth H Yu
PMID:
29447421
No abstract available
MeSH terms
Humans
Neoadjuvant Therapy / adverse effects
Pancreatectomy
Pancreatic Neoplasms / therapy*
Standard of Care